# AstraZeneca to build $475M small molecule drug plant in Wuxi, China

AstraZeneca has signed an agreement to invest $475 million to build a new small molecule drug manufacturing facility in Wuxi, Jiangsu, China. The plant will produce specific small molecule drugs for both Chinese and global markets.

- Type: New facility
- Announced: 2024-03-01
- Where: Wuxi, Jiangsu, China
- Value: $475.0M
- Status: announced
- Products: small molecule drugs

## Companies

- [AstraZeneca](https://endata.com/companies/35467.md)

## Sources

- [astrazeneca.com](https://www.astrazeneca.com/content/az-cn-zh/media/press-releases/2024/03-01-01.html), 2024-03-01: "我们很高兴此次在无锡投资4.75亿美元新建小分子药物工厂，无锡是我们在华发展30多年的首站。"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.